Show simple item record

dc.contributor.authorHarmer, Catherine J
dc.date.accessioned2021-02-16T15:43:41Z
dc.date.available2021-02-16T15:43:41Z
dc.date.issued2021-01
dc.identifier.citationAhmed N, Bone JK, Lewis G, Freemantle N, Harmer CJ, Duffy L, Lewis G (2021). The effect of sertraline on emotional processing: secondary analyses of the PANDA randomised controlled trial. Psychological Medicine 1–8.en
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/720
dc.description.abstractBackground. According to the cognitive neuropsychological model, antidepressants reduce symptoms of depression and anxiety by increasing positive relative to negative information processing. Most studies of whether antidepressants alter emotional processing use small samples of healthy individuals, which lead to low statistical power and selection bias and are difficult to generalise to clinical practice. We tested whether the selective serotonin reuptake inhibitor (SSRI) sertraline altered recall of positive and negative information in a large randomised controlled trial (RCT) of patients with depressive symptoms recruited from primary care. Methods. The PANDA trial was a pragmatic multicentre double-blind RCT comparing sertraline with placebo. Memory for personality descriptors was tested at baseline and 2 and 6 weeks after randomisation using a computerised emotional categorisation task followed by a free recall. We measured the number of positive and negative words correctly recalled (hits). Poisson mixed models were used to analyse longitudinal associations between treatment allocation and hits. Results. A total of 576 participants (88% of those randomised) completed the recall task at 2 and 6 weeks. We found no evidence that positive or negative hits differed according to treatment allocation at 2 or 6 weeks (adjusted positive hits ratio = 0.97, 95% CI 0.90–1.05, p = 0.52; adjusted negative hits ratio = 0.99, 95% CI 0.90–1.08, p = 0.76). Conclusions. In the largest individual placebo-controlled trial of an antidepressant not funded by the pharmaceutical industry, we found no evidence that sertraline altered positive or negative recall early in treatment. These findings challenge some assumptions of the cognitive neuropsychological model of antidepressant actionen
dc.description.sponsorshipSupported by the NIHRen
dc.description.urihttps://doi.org/10.1017/ S0033291720004985en
dc.language.isoenen
dc.subjectAntidepressant Drugsen
dc.subjectMemoryen
dc.subjectDepressive Disordersen
dc.subjectEmotional Processingen
dc.titleThe effect of sertraline on emotional processing: secondary analyses of the PANDA randomised controlled trialen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record